Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Zoom Video Communications, Inc. (ZM) Price & Performance

BridgeBio Pharma IncTrade
Zoom Video Communications, Inc.Trade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Zoom Video Communications, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.85 (market cap $16.36B), while Zoom Video Communications, Inc. trades at $104.69 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.

BBIOZM
Market Cap
$16.36B$31.10B
Sector
HealthTechnology
52-Week High
$90.17$111.88
52-Week Low
$47.29$69.96
Enterprise Value
$18.14B$23.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.

The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.

Zoom Video Communications, Inc.

Zoom Communications (ZM) trades at $104.70, down 2.33% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.4% gross margins and 42% net income margin, though recent earnings show volatility with one miss in the last four quarters. Recent news highlights CEO and director stock sales totaling over $7 million in July-August 2026, while the company continues AI product development and APAC expansion.

Outlook remains cautiously optimistic with a $118.79 consensus price target representing 13% upside potential. Key opportunities include sustained profitability and AI-driven growth initiatives, while risks center on insider selling pressure and competitive threats in the video communications space. The stock faces near-term technical resistance at $107-$109 levels with support at $103-$105.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Zoom Video Communications, Inc.

Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.

Read more on ZM